Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.

Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L.

Am J Psychiatry. 1999 Jun;156(6):869-75.

PMID:
10360125
2.
3.
4.

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S.

Am J Psychiatry. 1998 Jul;155(7):921-8.

PMID:
9659858
5.

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.

JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891.

PMID:
26131622
6.

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.

Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S.

Am J Psychiatry. 2006 Mar;163(3):396-401.

PMID:
16513859
7.

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.

Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R.

Psychopharmacology (Berl). 1998 Jan;135(2):119-26.

PMID:
9497016
8.

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G.

Biol Psychiatry. 1993 Feb 15;33(4):227-35.

PMID:
8097114
9.

D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.

Regenthal R, Kunstler U, Hesse S, Sabri O, Preiss R.

Int J Clin Pharmacol Ther. 2005 Aug;43(8):370-8.

PMID:
16119512
10.

Implications of brain imaging for the management of schizophrenia.

Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S15-20. Review.

PMID:
9690965
11.

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.

Am J Psychiatry. 2007 Sep;164(9):1411-7.

PMID:
17728427
12.

Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.

Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.

J Nucl Med. 1998 Jul;39(7):1138-42.

13.

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB.

J Clin Psychiatry. 2002 Nov;63(11):992-7.

PMID:
12444812
14.

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.

Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R.

Am J Psychiatry. 1996 Jul;153(7):948-50.

PMID:
8659621
15.

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Kapur S, Zipursky R, Jones C, Remington G, Houle S.

Am J Psychiatry. 2000 Apr;157(4):514-20.

PMID:
10739409
16.

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T.

Psychopharmacology (Berl). 2008 Apr;197(2):229-35.

PMID:
18058087
17.

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G.

Am J Psychiatry. 1995 Oct;152(10):1444-9.

PMID:
7573582
18.

Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men.

Andrée B, Halldin C, Vrijmoed-de Vries M, Farde L.

Psychopharmacology (Berl). 1997 Jun;131(4):339-45.

PMID:
9226735
19.

PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics.

Goyer PF, Berridge MS, Morris ED, Semple WE, Compton-Toth BA, Schulz SC, Wong DF, Miraldi F, Meltzer HY.

J Nucl Med. 1996 Jul;37(7):1122-7.

20.

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.

Am J Psychiatry. 2004 May;161(5):818-25.

PMID:
15121646
Items per page

Supplemental Content

Support Center